Water-soluble β-cyclodextrins in paediatric oral solutions of spironolactone: Solubilization and stability of spironolactone in solutions of β-cyclodextrin derivatives

International Journal of Pharmaceutics

Volumn 159, Issue 2, 1997, Pages 159-170

  Kaukonen, Ann M ^a   Kilpeläinen, Ilkka ^b   Mannermaa, Jukka Pekka ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Inclusion complex; Paediatric; Solubilization; Spironolactone; Stability; Temperature dependence; Water soluble cyclodextrins

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; DIMETHYL BETA CYCLODEXTRIN; HEPTAKIS(2,6 O DIMETHYL) BETA CYCLODEXTRIN; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; SULPHOBUTYL ETHER BETA CYCLODEXTRIN; UNCLASSIFIED DRUG; WATER;

ARTICLE; DEACETYLATION; DRUG DEGRADATION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; ENTERIC FEEDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PEDIATRICS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; THERMOSTABILITY;

EID: 0344073961     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)00280-9     Document Type: Article

References (24)

1. Atkinson S.A., Shah J.K., McGee C., Steele B.T. Mineral excretion in premature infants receiving various diuretic therapies. J. Pediatr. 113:1988;540-545.
2. Committee on Extemporaneous Formulations, 1987. ASHP Special Interest Group on Pediatric Pharmacy Practice, Handbook on Extemporaneous Formulations. American Society of Hospital Pharmacists, Bethesda, MD, pp. 45-47.
3. Debruères B., Brétillon A., Duchêne D. Improvement of solubility and bioavailability of spironolactone by inclusion in β-cyclodextrin. Proc. Int. Symp. Control. Release Bioact. Mater. 12:1985;118-119.
4. ™ HPB, hydroxypropyl-β-cyclodextrin, after oral and iv administration. 8th International Cyclodextrin Symposium, March 30-April 2, 1996, Budapest, Hungary.
5. Higuchi T., Connors K.A. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 4:1965;117-212.
6. Kaukonen, A.M., Vuorela, P., Vuorela, H., Mannermaa, J.-P., 1997. HPLC-methods for the separation and quantitation of spironolactone and its degradation products in aqueous formulations or metabolites in rat serum. J. Chromatogr. Submitted.
7. Leff R., Roberts R. Problems in drug therapy of pediatric patients. Am. J. Hosp. Pharm. 44:1987;865-870.
8. McInnes G.T., Asbury M.J., Shelton J.R., Harrison I.R., Ramsay L.E., Venning G.R., Clarke J.M. Activity of sulfur-containing intermediate metabolites of spironolactone. Clin. Pharmacol. Ther. 27:1980;363-369.
9. Mathur L.K., Wickman A. Stability of extemporaneously compounded spironolactone suspensions. Am. J. Hosp. Pharm. 46:1989;2040-2042.
10. Overdiek H.W.P.M., Hermens W.A.J.J., Merkus F.W.H.M. New insights into the pharmacokinetics of spironolactone. Clin. Pharmacol. Ther. 38:1985;469-474.
11. Pitha J., Milecki J., Fales H., Pannell L., Uekama K. Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs. Int. J. Pharm. 29:1986;73-82.
12. Pramar Y., Gupta V.D., Bethea C. Development of a stable oral liquid dosage form of spironolactone. J. Clin. Pharm. Ther. 17:1992;245-248.
13. Seo H., Tsuruoka M., Hashimoto T., Fujinaga T., Otagiri M., Uekama K. Enhancement of oral bioavailability of spironolactone by β- and γ-cyclodextrin complexations. Chem. Pharm. Bull. 31:1983;286-291.
14. Sutter, J.L., Lau, E.P.K., 1975. Spironolactone. In: Florey, K. (Ed.), Analytical Profiles of Drug Substances. Vol. 4. Academic Press, New York, pp. 431-451.
15. Szatmári, I., Vargay, Z., 1988. Pharmacokinetics of dimethyl-beta-cyclodextrin in rats, in Duchêne, D. (Ed.), Proceedings of the 4th International Symposium on Cyclodextrins, Kluwer, Dordrecht, pp. 407-413.
16. Szejtli, J., 1988. Cyclodextrins in pharmaceuticals. Cyclodextrin Technology, Kluwer, Dordrecht, pp. 186-306.
17. Thompson D. Cyclodextrins - enabling excipients: Their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst. 14:1997;1-104.
18. Tötterman A.M., Schipper N.G.M., Thompson D., Mannermaa J.-P. Intestinal safety of water-soluble β-cyclodextrins in paediatric oral solutions of spironolactone: Effects on human intestinal epithelial Caco-2 cells. J. Pharm. Pharmacol. 49:1997;43-48.
19. Varin F., Tu T.M., Benoît F., Villeneuve J.-P., Théorêt Y. High-performance liquid chromatographic determination of spironolactone and its metabolites in human biological fluids after solid-phase extraction. J. Chromatogr. 574:1992;57-64.
20. Vila-Jato J., Blanco J., Vilar A. Spironolactone/β-cyclodextrin complex: Oral bioavailability in humans. Acta Pharm. Technol. 32:1986;82-85.
21. Wouessidjewe D., Crassous A., Duchêne D., Coleman A., Rysanek N., Tsoucaris G., Perly B., Djedaini F. Inclusion of spironolactone in cyclomaltoheptaose: a guest affected by the hospitality of the host. Carbohydr. Res. 192:1989;313-322.
22. Uekama K. Pharmaceutical applications of methylated cyclodextrins. Pharm. Int. 6:1985;61-65.
23. Yusuff N., York P. Spironolactone-cyclodextrin complexes: phase solubility and ultrafiltration studies. Int. J. Pharm. 73:1991;9-15.
24. Yusuff N.T., York P., Chrystyn H., Bramley P.N., Swallow R.D., Tuladhar B.R., Losowsky M.S. Improved bioavailability from a spironolactone beta-cyclodextrin complex. Eur. J. Clin. Pharmacol. 40:1991;507-511.